SCHEMBL23112253

SCHEMBL23112253

CC1(C)c2ccccc2-c2c(-c3ccc(-c4ccc(-c5ccccc5)cc4)cc3)nc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 6/20 0.42
LMNA P02545 3/20 0.42
HPGD P15428 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GLA P06280 1/20 0.42
MAPT P10636 2/20 0.38
L3MBTL1 Q9Y468 4/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
GAA P10253 1/20 0.34
PDK2 Q15119 1/20 0.34
OPRK1 P41145 1/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
PKM P14618 1/20 0.32
PTGS2 P35354 2/20 0.31
PTGS1 P23219 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31201811 1.00 KDM4E (0.42) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL23112254 0.79 AHR (0.38) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL20659750 0.78 TSHR (0.31)
SCHEMBL18942944 0.77 KDM4E (0.47) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL23112257 0.76 KDM4E (0.42) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL12952469 0.75 NUDT1 (0.34) KDM4EALDH1A1LMNAHPGDMAPT
SCHEMBL19758808 0.75 ALDH1A1 (0.41) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL23770429 0.73 L3MBTL1 (0.36) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL30205798 0.73 L3MBTL1 (0.36) KDM4EALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL20659888 0.73 MEN1 (0.31) MAPTKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2024-01-02 US disclosed
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2024-01-02 US disclosed
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same LG CHEM, LTD. (KR) 2024-01-02 US disclosed
US-20210340159-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG CHEM, LTD. (KR) 2021-11-04 US disclosed
EP-3795569-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME LG CHEM, LTD. (KR) 2021-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340159-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME NR4A1, CYP1A1, ARNT KDM4E 2596/4885ALDH1A1 228/4885LMNA 2919/4885
US-11858947-B2 Heterocyclic compound and organic light emitting device including the same NR4A1, CYP1A1, ARNT KDM4E 2596/4885ALDH1A1 228/4885LMNA 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.